bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, with the potential to dramatically increase overall diagnostic accuracy of lung cancer leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.
In vitro Diagnostics
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
Commercial Physical and Biological Research (8731)
Tiberend Strategic Advisors, Inc.
35 W. 35th Street
New York, NY 10001-0080
bioAffinity Technologies, Inc.
22211 West Interstate 10
San Antonio, TX 78257